Abstract
Precision medicine uses innovative approaches to improve disease prevention and treatment outcomes by taking into account people’s genetic backgrounds, environments, and lifestyles. Treatment of depression is particularly challenging, given that 30–50% of patients do not respond adequately to antidepressants, while those who respond may experience unpleasant adverse drug reactions (ADRs) that decrease their quality of life and compliance. This chapter aims to present the available scientific data that focus on the impact of genetic variants on the efficacy and toxicity of antidepressants. We compiled data from candidate gene and genome-wide association studies that investigated associations between pharmacodynamic and pharmacokinetic genes and response to antidepressants regarding symptom improvement and ADRs. We also summarized the existing pharmacogenetic-based treatment guidelines for antidepressants, used to guide the selection of the right antidepressant and its dose based on the patient's genetic profile, aiming to achieve maximum efficacy and minimum toxicity. Finally, we reviewed the clinical implementation of pharmacogenomics studies focusing on patients on antidepressants. The available data demonstrate that precision medicine can increase the efficacy of antidepressants and reduce the occurrence of ADRs and ultimately improve patients’ quality of life.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Change history
15 July 2023
A correction has been published.
References
Abaut AY, Chevanne F, Le Corre P (2007) Oral bioavailability and intestinal secretion of amitriptyline: role of P-glycoprotein? Int J Pharm 330:121–128. https://doi.org/10.1016/J.IJPHARM.2006.09.026
Adkins DE, Clark SL, Åberg K et al (2012) Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D. Transl Psychiatry 2. https://doi.org/10.1038/TP.2012.57
Amare AT, Schubert KO, Tekola-Ayele F et al (2018) Association of the polygenic scores for personality traits and response to selective serotonin reuptake inhibitors in patients with major depressive disorder. Front Psych 9. https://doi.org/10.3389/FPSYT.2018.00065
Angus JA, Black JW (1980) Pharmacological assay of cardiac H2-receptor blockade by amitriptyline and lysergic acid diethylamide. Circ Res 46
Arndt P, Volk C, Gorboulev V et al (2001) Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol 281. https://doi.org/10.1152/AJPRENAL.2001.281.3.F454
Athanasiu L, Smorr LLH, Tesli M et al (2015) Genome-wide association study identifies common variants associated with pharmacokinetics of psychotropic drugs. J Psychopharmacol 29:884–891. https://doi.org/10.1177/0269881115584469
Avery CL, Sitlani CM, Arking DE et al (2014) Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J 14:6–13. https://doi.org/10.1038/TPJ.2013.4
Barańczyk-Kuźma A, Kuźma M, Gutowicz M et al (2004) Glutathione S-transferase pi as a target for tricyclic antidepressants in human brain. Acta Biochim Pol 51:10.18388/abp.2004_3612
Baumann P (1996a) Pharmacology and pharmacokinetics of citalopram and other SSRIs. Int Clin Psychopharmacol 11(Suppl 1):5–11. https://doi.org/10.1097/00004850-199603001-00002
Baumann P (1996b) Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444–469. https://doi.org/10.2165/00003088-199631060-00004
Baune BT, Hohoff C, Roehrs T et al (2008) Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci Lett 436:111–115. https://doi.org/10.1016/J.NEULET.2008.03.001
Béïque JC, Lavoie N, De Montigny C, Debonnel G (1998) Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters. Eur J Pharmacol 349:129–132. https://doi.org/10.1016/S0014-2999(98)00241-6
Biernacka JM, Sangkuhl K, Jenkins G et al (2015) The international SSRI pharmacogenomics consortium (ISPC): a genome-wide association study of antidepressant treatment response. Transl Psychiatry 5:e553–e553. https://doi.org/10.1038/tp.2015.47
Binder EB, Owens MJ, Liu W et al (2010) Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry 67:369–379. https://doi.org/10.1001/ARCHGENPSYCHIATRY.2010.18
Bishop JR, Moline J, Ellingrod VL et al (2006) Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 31:2281–2288. https://doi.org/10.1038/SJ.NPP.1301090
Bishop JR, Najjar F, Rubin LH et al (2015) Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics 25:548–554. https://doi.org/10.1097/FPC.0000000000000173
Borobia AM, Novalbos J, Guerra-López P et al (2009) Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacol Res 59:393–398. https://doi.org/10.1016/J.PHRS.2009.02.006
Bousman CA, Arandjelovic K, Mancuso SG et al (2019) Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics 20:37–47. https://doi.org/10.2217/PGS-2018-0142
Bousman CA, Bengesser SA, Aitchison KJ et al (2021) Review and consensus on pharmacogenomic testing in psychiatry. Pharmacopsychiatry 54:5–17. https://doi.org/10.1055/a-1288-1061
Bozymski KM, Crouse EL, Titus-Lay EN et al (2020) Esketamine: a novel option for treatment-resistant depression. Ann Pharmacother 54:567–576. https://doi.org/10.1177/1060028019892644
Bradley P, Shiekh M, Mehra V et al (2018) Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res 96:100–107. https://doi.org/10.1016/J.JPSYCHIRES.2017.09.024
Bråten LS, Haslemo T, Jukic MM et al (2020) Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology 45:570–576. https://doi.org/10.1038/S41386-019-0554-X
Breitenstein B, Brückl TM, Ising M et al (2015) ABCB1 gene variants and antidepressant treatment outcome: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 168B:274–283. https://doi.org/10.1002/AJMG.B.32309
Breitenstein B, Scheuer S, Brückl TM et al (2016) Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: results from a randomized clinical study. J Psychiatr Res 73:86–95. https://doi.org/10.1016/J.JPSYCHIRES.2015.11.010
Brinkschulte M, Breyer-Pfaff U (1980) The contribution of alpha 1-acid glycoprotein, lipoproteins, and albumin to the plasma binding of perazine, amitriptyline, and nortriptyline in healthy man. Naunyn Schmiedebergs Arch Pharmacol 314:61–66. https://doi.org/10.1007/BF00498432
Brown JT, Schneiderhan M, Eum S, Bishop JR (2017) Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics 18:601–605. https://doi.org/10.2217/PGS-2017-0015
Brown LC, Stanton JD, Bharthi K et al (2022) Pharmacogenomic testing and depressive symptom remission: a systematic review and meta-analysis of prospective, controlled clinical trials. Clin Pharmacol Ther. https://doi.org/10.1002/CPT.2748
Bryson HM, Wilde MI (1996) Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 8:459–476. https://doi.org/10.2165/00002512-199608060-00008
Bymaster F, Lee T, Knadler M et al (2005) The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11:1475–1493. https://doi.org/10.2174/1381612053764805
Caccia S (1998) Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34:281–302. https://doi.org/10.2165/00003088-199834040-00002
Carter NJ, McCormack PL (2009) Duloxetine: a review of its use in the treatment of generalized anxiety disorder. CNS Drugs 23:523–541. https://doi.org/10.2165/00023210-200923060-00006
Casis O, Sánchez-Chapula JA (1998) Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol 32:521–526. https://doi.org/10.1097/00005344-199810000-00003
Cellini L, de Donatis D, Zernig G et al (2022) Antidepressant efficacy is correlated with plasma levels: mega-analysis and further evidence. Int Clin Psychopharmacol 37:29–37. https://doi.org/10.1097/YIC.0000000000000386
Chan CY, New LS, Ho HK, Chan ECY (2011) Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivation. Toxicol Lett 206:314–324. https://doi.org/10.1016/J.TOXLET.2011.07.019
Chen H, Brzezinski MR, Fantel AG, Juchau MR (1999) Catalysis of drug oxidation during embryogenesis in human hepatic tissues using imipramine as a model substrate. Drug Metab Dispos 27
Cicali EJ, Weitzel KW, Elsey AR et al (2019) Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. Genet Med 21:2264–2274. https://doi.org/10.1038/S41436-019-0500-7
Clark SL, Adkins DE, Aberg K et al (2012) Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med 42:1151–1162. https://doi.org/10.1017/S003329171100239X
Connelly WM, Shenton FC, Lethbridge N et al (2009) The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157:55–63. https://doi.org/10.1111/J.1476-5381.2009.00227.X
Contreras CM, Marván ML, Muñoz-Méndez A, Ramírez-Morales A (1992) Cortical and septal responses to dorsal raphe nucleus stimulation in the rat: long-term clomipramine actions. Bol Estud Med Biol 40
Corponi F, Fabbri C, Serretti A (2018) Pharmacogenetics in psychiatry. Adv Pharmacol 83:297–331. https://doi.org/10.1016/bs.apha.2018.03.003
Correia C, Alcobia L, Lopes MJ, Advinha AM (2022) Pharmacogenomic biomarkers as source of evidence of the effectiveness and safety of antidepressant therapy. BMC Psychiatry 22. https://doi.org/10.1186/S12888-022-04225-2
Cusack B, Nelson A, Richelson E (1994) Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 114:559–565. https://doi.org/10.1007/BF02244985
Davis BA, Nagarajan A, Forrest LR, Singh SK (2016) Mechanism of paroxetine (Paxil) inhibition of the serotonin transporter. Sci Rep 6. https://doi.org/10.1038/SREP23789
Dawson LA, Nguyen HQ, Geiger A (1999) Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT(1A) receptor antagonism. Neuropharmacology 38:1153–1163. https://doi.org/10.1016/S0028-3908(99)00052-0
DeVane CL, Donovan JL, Liston HL et al (2004) Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol 24:4–10. https://doi.org/10.1097/01.JCP.0000104908.75206.26
Di Matteo V, De Blasi A, Di Giulio C, Esposito E (2001) Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 22:229–232. https://doi.org/10.1016/S0165-6147(00)01688-6
Dilsaver SC, Snider RM, Alessi NE (1987) Amitriptyline supersensitizes a central cholinergic mechanism. Biol Psychiatry 22:495–507. https://doi.org/10.1016/0006-3223(87)90171-5
Duncan RS, McPate MJ, Ridley JM et al (2007) Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 74:425–437. https://doi.org/10.1016/J.BCP.2007.04.024
Eap CB, Bondolfi G, Zullino D et al (2001) Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 21:330–334. https://doi.org/10.1097/00004714-200106000-00013
Ehlert FJ, Delen FM, Yun SH, Liem HA (1990) The interaction of amitriptyline, doxepin, imipramine and their N-methyl quaternary ammonium derivatives with subtypes of muscarinic receptors in brain and heart. J Pharmacol Exp Ther 253
Fabbri C, Di Girolamo G, Serretti A (2013) Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet 162B:487–520. https://doi.org/10.1002/AJMG.B.32184
Fabbri C, Crisafulli C, Calabrò M et al (2016) Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opin Drug Metab Toxicol 12:1157–1168. https://doi.org/10.1080/17425255.2016.1202237
Fabbri C, Tansey KE, Perlis RH et al (2018a) New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. Pharmacogenomics J 18:413–421. https://doi.org/10.1038/TPJ.2017.44
Fabbri C, Tansey KE, Perlis RH et al (2018b) Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies. Eur Neuropsychopharmacol 28:945–954. https://doi.org/10.1016/J.EURONEURO.2018.05.009
Fabbri C, Kasper S, Kautzky A et al (2019) Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. Br J Psychiatry 214:36–41. https://doi.org/10.1192/BJP.2018.256
Ferry DG, Caplan NB, Cubeddu LX (1986) Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci 75:146–149. https://doi.org/10.1002/JPS.2600750208
Figueiredo A, Ribeiro CF, Gonçalo M et al (1990) Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol 4:147–158. https://doi.org/10.1111/J.1472-8206.1990.TB00482.X
Fishback JA, Robson MJ, Xu YT, Matsumoto RR (2010) Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther 127:271–282. https://doi.org/10.1016/J.PHARMTHERA.2010.04.003
Fjukstad KK, Athanasiu L, Bahrami S et al (2021) Genetic variants associated with cardiometabolic abnormalities during treatment with selective serotonin reuptake inhibitors: a genome-wide association study. Pharmacogenomics J 21:574–585. https://doi.org/10.1038/S41397-021-00234-8
Fogelman SM, Schmider J, Venkatakrishnan K et al (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480–490. https://doi.org/10.1016/S0893-133X(98)00113-4
Foster RH, Goa KL (1997) Paroxetine: a review of its pharmacology and therapeutic potential in the management of panic disorder. CNS Drugs 8:163–188. https://doi.org/10.2165/00023210-199708020-00010
Friemel A, Zünkler BJ (2010) Interactions at human ether-à-go-go-related gene channels. Toxicol Sci 114:346–355. https://doi.org/10.1093/TOXSCI/KFQ011
Fujishiro J, Imanishi T, Onozawa K, Tsushima M (2002) Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol 454:183–188. https://doi.org/10.1016/S0014-2999(02)02557-8
Furukawa TA, Cipriani A, Cowen PJ et al (2019) Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry 6:601–609. https://doi.org/10.1016/S2215-0366(19)30217-2
Gadad BS, Raj P, Jha MK et al (2018) Association of novel ALX4 gene polymorphisms with antidepressant treatment response: findings from the CO-MED trial. Mol Neuropsychiatry 4:7–19. https://doi.org/10.1159/000487321
García-Colunga J, Awad JN, Miledi R (1997) Blockage of muscle and neuronal nicotinic acetylcholine receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A 94:2041–2044. https://doi.org/10.1073/PNAS.94.5.2041
Garcïa-Ferreiro RE, Kerschensteiner D, Major F et al (2004) Mechanism of block of hEag1 K+ channels by imipramine and astemizole. J Gen Physiol 124:301–317. https://doi.org/10.1085/JGP.200409041
Garriock HA, Kraft JB, Shyn SI et al (2010) A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 67:133–138. https://doi.org/10.1016/j.biopsych.2009.08.029
Gaynes BN, Warden D, Trivedi MH et al (2009) What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60(1439–1):445. https://doi.org/10.1176/PS.2009.60.11.1439
Ghahramani P, Ellis SW, Lennard MS et al (1997) Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol 43:137–144. https://doi.org/10.1046/J.1365-2125.1997.05382.X
Giacomini KM, Yee SW, Mushiroda T et al (2017) Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat Rev Drug Discov 16:1. https://doi.org/10.1038/NRD.2016.234
Glatt CE, Lee FS (2016) Common polymorphisms in the age of research domain criteria (RDoC): integration and translation. Biol Psychiatry 79:25–31. https://doi.org/10.1016/J.BIOPSYCH.2014.12.020
Goldberg JF (2019) Does pharmacogenomic testing meaningfully improve antidepressant treatment outcomes when looking only at patients taking phase I hepatically metabolized drugs? A little. J Clin Psychiatry 80. https://doi.org/10.4088/JCP.19COM13119
Gören MZ, Küçükibrahimoglu E, Berkman K, Terzioglu B (2007) Fluoxetine partly exerts its actions through GABA: a neurochemical evidence. Neurochem Res 32:1559–1565. https://doi.org/10.1007/S11064-007-9357-2
Gould GG, Altamirano AV, Javors MA, Frazer A (2006) A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters. Biol Psychiatry 59:408–414. https://doi.org/10.1016/J.BIOPSYCH.2005.07.011
Govindarajan A, Shankaranarayana Rao BS, Nair D et al (2006) Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci U S A 103:13208–13213. https://doi.org/10.1073/PNAS.0605180103
Greden JF, Parikh SV, Rothschild AJ et al (2019) Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res 111:59–67. https://doi.org/10.1016/J.JPSYCHIRES.2019.01.003
Green A, Crawford A, Button KS et al (2014) Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial. J Affect Disord 163:40–46. https://doi.org/10.1016/J.JAD.2014.03.051
Gründemann D, Gorboulev V, Gambaryan S et al (1994) Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372:549–552. https://doi.org/10.1038/372549A0
Haddjeri N, Blier P, De Montigny C (1998) Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J Neurosci 18:10150–10156. https://doi.org/10.1523/JNEUROSCI.18-23-10150.1998
Haenisch B, Bönisch H (2010) Interaction of the human plasma membrane monoamine transporter (hPMAT) with antidepressants and antipsychotics. Naunyn Schmiedebergs Arch Pharmacol 381:33–39. https://doi.org/10.1007/S00210-009-0479-8
Hall-Flavin DK, Winner JG, Allen JD et al (2012) Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry 2. https://doi.org/10.1038/TP.2012.99
Hall-Flavin DK, Winner JG, Allen JD et al (2013) Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics 23:535–548. https://doi.org/10.1097/FPC.0B013E3283649B9A
Halling J, Weihe P, Brosen K (2008) The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol 65:134–138. https://doi.org/10.1111/J.1365-2125.2007.02969.X
Hamon M, Gozlan H, Bourgoin S et al (1987) Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 26:531–539. https://doi.org/10.1016/0028-3908(87)90144-4
Han C, Wang S-M, Bahk W-M et al (2018) A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin Psychopharmacol Neurosci 16:469–480. https://doi.org/10.9758/CPN.2018.16.4.469
Härtter S, Tybring G, Friedberg T et al (2002) The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 19:1034–1037. https://doi.org/10.1023/A:1016478708902
Hayashi Y, Watanabe T, Aoki A et al (2015) Factors affecting steady-state plasma concentrations of enantiomeric mirtazapine and its desmethylated metabolites in Japanese psychiatric patients. Pharmacopsychiatry 48:279–285. https://doi.org/10.1055/S-0035-1565069
Hennings JM, Owashi T, Binder EB et al (2009) Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – findings from the Munich antidepressant response signature (MARS) project. J Psychiatr Res 43:215–229. https://doi.org/10.1016/J.JPSYCHIRES.2008.05.002
Hermann M, Hendset M, Fosaas K et al (2008) Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 64:483–487. https://doi.org/10.1007/S00228-007-0453-7
Hervé F, Duché JC, D’Athis P et al (1996) Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics 6:403–415. https://doi.org/10.1097/00008571-199610000-00004
Hesse LM, Venkatakrishnan K, Court MH et al (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28
Hicks JK, Sangkuhl K, Swen JJ et al (2017) Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 102:37–44. https://doi.org/10.1002/cpt.597
Hiemke C, Bergemann N, Clement HW et al (2018) Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 51:9–62. https://doi.org/10.1055/S-0043-116492
Hodgson K, Tansey K, Dernovšek MZ et al (2014) Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol 28:133–141. https://doi.org/10.1177/0269881113512041
Hoehe MR, Morris-Rosendahl DJ (2018) The role of genetics and genomics in clinical psychiatry. Dialogues Clin Neurosci 20:169–177
Hoffelt C, Gross T (2016) A review of significant pharmacokinetic drug interactions with antidepressants and their management. Ment Heal Clin 6:35–41. https://doi.org/10.9740/MHC.2016.01.035
Hu Q, Zhang SY, Liu F et al (2015) Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis. J Affect Disord 172:103–109. https://doi.org/10.1016/J.JAD.2014.09.039
Huddart R, Hicks JK, Ramsey LB et al (2020) PharmGKB summary: sertraline pathway, pharmacokinetics. Pharmacogenet Genomics 30:26–33. https://doi.org/10.1097/FPC.0000000000000392
Huezo-Diaz P, Perroud N, Spencer EP et al (2012) CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 26:398–407. https://doi.org/10.1177/0269881111414451
Hunter AM, Leuchter AF, Power RA et al (2013) A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res 47:1157–1165. https://doi.org/10.1016/J.JPSYCHIRES.2013.05.002
Hunziker ME, Suehs BT, Bettinger TL, Crismon ML (2005) Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 27:1126–1143. https://doi.org/10.1016/J.CLINTHERA.2005.08.010
Hurwitz R, Ferlinz K, Sandhofl K (1994) The tricyclic antidepressant desipramine causes proteolytic degradation of lysosomal sphingomyelinase in human fibroblasts. Biol Chem Hoppe Seyler 375:447–450. https://doi.org/10.1515/BCHM3.1994.375.7.447
Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13. https://doi.org/10.1038/SJ.TPJ.6500285
Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526. https://doi.org/10.1016/j.pharmthera.2007.09.004
Ising M, Lucae S, Binder EB et al (2009) A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66:966. https://doi.org/10.1001/archgenpsychiatry.2009.95
Islam F, Marshe VS, Magarbeh L et al (2022) Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study. Transl Psychiatry 12. https://doi.org/10.1038/S41398-022-02124-4
Isobe T, Hichiya H, Hanioka N et al (2005) Different effects of desipramine on bufuralol 1″-hydroxylation by rat and human CYP2D enzymes. Biol Pharm Bull 28:634–640. https://doi.org/10.1248/BPB.28.634
James SL, Abate D, Abate KH et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858. https://doi.org/10.1016/S0140-6736(18)32279-7
Jang SW, Liu X, Chan CB et al (2009) Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 16:644–656. https://doi.org/10.1016/J.CHEMBIOL.2009.05.010
Jann MW, ZumBrunnen TL, Kazmi YR et al (2002) Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. Drug Metabol Drug Interact 19:1–11. https://doi.org/10.1515/DMDI.2002.19.1.1
Jarvis JP, Peter AP, Shaman JA (2019) Consequences of CYP2D6 copy-number variation for pharmacogenomics in psychiatry. Front Psych 10:432. https://doi.org/10.3389/fpsyt.2019.00432
Jenck F, Moreau JL, Mutel V et al (1993) Evidence for a role of 5-HT1C receptors in the antiserotonergic properties of some antidepressant drugs. Eur J Pharmacol 231:223–229. https://doi.org/10.1016/0014-2999(93)90453-O
Jeppesen U, Gram LF, Vistisen K et al (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73–78. https://doi.org/10.1007/S002280050163
Ji Y, Biernacka JM, Hebbring S et al (2013) Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J 13:456–463. https://doi.org/10.1038/TPJ.2012.32
Ji Y, Schaid DJ, Desta Z et al (2014) Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol 78:373–383. https://doi.org/10.1111/BCP.12348
Jiang ZP, Shu Y, Chen XP et al (2002) The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur J Clin Pharmacol 58:109–113. https://doi.org/10.1007/S00228-002-0445-6
Jo SH, Youm JB, Lee CO et al (2000) Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol 129:1474–1480. https://doi.org/10.1038/SJ.BJP.0703222
Joyce PR, Mulder RT, Luty SE et al (2003) Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 6:339–346. https://doi.org/10.1017/S1461145703003663
Jukić MM, Haslemo T, Molden E, Ingelman-Sundberg M (2018) Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry 175:463–470. https://doi.org/10.1176/APPI.AJP.2017.17050550
Jung J, Tawa EA, Muench C et al (2017) Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res 254:8–11. https://doi.org/10.1016/J.PSYCHRES.2017.04.025
Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15:473–500. https://doi.org/10.1038/MP.2008.116
Kendrick T (2021) Strategies to reduce use of antidepressants. Br J Clin Pharmacol 87:23–33. https://doi.org/10.1111/bcp.14475
Kim H, Lim SW, Kim S et al (2006) Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 296:1609–1618. https://doi.org/10.1001/JAMA.296.13.1609
Kirchheiner J, Henckel HB, Meineke I et al (2004a) Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 24:647–652. https://doi.org/10.1097/01.JCP.0000145341.30547.F0
Kirchheiner J, Nickchen K, Bauer M et al (2004b) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442–473. https://doi.org/10.1038/sj.mp.4001494
Knadler MP, Lobo E, Chappell J, Bergstrom R (2011) Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 50:281–294. https://doi.org/10.2165/11539240-000000000-00000
Köhler-Forsberg O, Larsen ER, Buttenschon HN et al (2019) Effect of antidepressant switching between nortriptyline and escitalopram after a failed first antidepressant treatment among patients with major depressive disorder. Br J Psychiatry 215:494–501. https://doi.org/10.1192/BJP.2018.302
Kordou Z, Skokou M, Tsermpini E-E et al (2021) Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data. Pharmacol Res 167:105538. https://doi.org/10.1016/j.phrs.2021.105538
Koyama E, Chiba K, Tani M, Ishizaki T (1997) Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281
Kraus C, Kadriu B, Lanzenberger R et al (2019) Prognosis and improved outcomes in major depression: a review. Transl Psychiatry 9:127. https://doi.org/10.1038/s41398-019-0460-3
Krishnan A, Hariharan R, Nair SA, Pillai MR (2008) Fluoxetine mediates G0/G1 arrest by inducing functional inhibition of cyclin dependent kinase subunit (CKS)1. Biochem Pharmacol 75:1924–1934. https://doi.org/10.1016/J.BCP.2008.02.013
Laje G, Allen AS, Akula N et al (2009) Genome-wide association study of suicidal ideation emerging during citalopram treatment of depressed outpatients. Pharmacogenet Genomics 19:666–674. https://doi.org/10.1097/FPC.0B013E32832E4BCD
Lee SY, Sohn KM, Ryu JY et al (2006) Sequence-based CYP2D6 genotyping in the Korean population. Ther Drug Monit 28:382–387. https://doi.org/10.1097/01.FTD.0000211823.80854.DB
Lee HY, Kang RH, Paik JW et al (2009) Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Brain Res 1262:1–6. https://doi.org/10.1016/J.BRAINRES.2009.01.013
Li QS, Tian C, Seabrook GR et al (2016) Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response. Transl Psychiatry 6. https://doi.org/10.1038/TP.2016.171
Li QS, Tian C, Hinds D et al (2020) Genome-wide association studies of antidepressant class response and treatment-resistant depression. Transl Psychiatry 10. https://doi.org/10.1038/S41398-020-01035-6
Liebowitz MR, Tourian KA (2010) Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials. Prim Care Companion J Clin Psychiatry 12. https://doi.org/10.4088/PCC.09R00845BLU
Lin E, Kuo PH, Liu YL et al (2018) A deep learning approach for predicting antidepressant response in major depression using clinical and genetic biomarkers. Front Psych 9. https://doi.org/10.3389/FPSYT.2018.00290
Lin XQ, Wang P, Cai WK et al (2019) The associations between CYP2D6 metabolizer status and pharmacokinetics and clinical outcomes of venlafaxine: a systematic review and meta-analysis. Pharmacopsychiatry 52:222–231. https://doi.org/10.1055/A-0792-1340
Lind AB, Reis M, Bengtsson F et al (2009) Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 48:63–70. https://doi.org/10.2165/0003088-200948010-00005
Liu ZQ, Cheng ZN, Huang SL et al (2001) Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 52:96–99. https://doi.org/10.1046/J.0306-5251.2001.01402.X
Llerena A, Berecz R, De la Rubia A et al (2001) Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 23:616–620. https://doi.org/10.1097/00007691-200112000-00004
Lucchelli A, Santagostino-Barbone MG, D’Agostino G et al (2000) The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol 362:284–289. https://doi.org/10.1007/S002100000295
Maciukiewicz M, Marshe VS, Tiwari AK et al (2018) Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics J 18:406–412. https://doi.org/10.1038/TPJ.2017.29
Madsen H, Rasmussen BB, Brøsen K (1997) Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther 61:319–324. https://doi.org/10.1016/S0009-9236(97)90164-8
Mahar Doan KM, Humphreys JE, Webster LO et al (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029–1037. https://doi.org/10.1124/JPET.102.039255
Maines LW, Antonetti DA, Wolpert EB, Smith CD (2005) Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49:610–617. https://doi.org/10.1016/J.NEUROPHARM.2005.04.028
Maj J, Gancarczyk L, Gorszczyk E, Rawlow A (1977) Doxepin as a blocker of central serotonin receptors. Pharmakopsychiatr Neuropsychopharmakol 10:318–324. https://doi.org/10.1055/S-0028-1094556
Malhi GS, Mann JJ (2018) Depression. Lancet 392:2299–2312. https://doi.org/10.1016/S0140-6736(18)31948-2
Margolis JM, O’Donnell JP, Mankowski DC et al (2000) (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28
Marković AS, Petranović MZ, Tomas Ž et al (2022) Untangling SNP variations within CYP2D6 gene in Croatian Roma. J Pers Med 12. https://doi.org/10.3390/JPM12030374
Marshe VS, Maciukiewicz M, Hauschild AC et al (2021) Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Transl Psychiatry 11. https://doi.org/10.1038/S41398-021-01248-3
Masubuchi Y, Takahashii C, Fujio N et al (1995) Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Drug Metab Dispos 23
McDonnell AM, Dang CH (2013) Basic review of the cytochrome p450 system. J Adv Pract Oncol 4:263–268. https://doi.org/10.6004/jadpro.2013.4.4.7
McInnes G, Yee SW, Pershad Y, Altman RB (2021) Genomewide association studies in pharmacogenomics. Clin Pharmacol Ther 110:637–648. https://doi.org/10.1002/CPT.2349
McMahon FJ, Buervenich S, Charney D et al (2006) Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804–814. https://doi.org/10.1086/503820
Melikian HE, Buckley KM (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19:7699–7710. https://doi.org/10.1523/JNEUROSCI.19-18-07699.1999
Millan MJ, Veiga S, Girardon S, Brocco M (2003) Blockade of serotonin 5-HT1B and 5-HT2A receptors suppresses the induction of locomotor activity by 5-HT reuptake inhibitors, citalopram and fluvoxamine, in NMRI mice exposed to a novel environment: a comparison to other 5-HT receptor subtypes. Psychopharmacology (Berl) 168:397–409. https://doi.org/10.1007/S00213-003-1389-Y
Milosavljevic F, Bukvic N, Pavlovic Z et al (2021) Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiatry 78:270–280. https://doi.org/10.1001/jamapsychiatry.2020.3643
Monostory K, Hazai E, Vereczkey L (2004) Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact 147:331–340. https://doi.org/10.1016/j.cbi.2004.03.003
Mooney SD (2015) Progress towards the integration of pharmacogenomics in practice. Hum Genet 134:459–465. https://doi.org/10.1007/s00439-014-1484-7
Morinobu S, Tanaka T, Kawakatsu S et al (1997) Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci 51:253–257. https://doi.org/10.1111/J.1440-1819.1997.TB02593.X
Mrazek DA, Lerman C (2011) Facilitating clinical implementation of pharmacogenomics. JAMA 306:304–305. https://doi.org/10.1001/JAMA.2011.1010
Mrazek DA, Rush AJ, Biernacka JM et al (2009) SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 150B:341–351. https://doi.org/10.1002/AJMG.B.30816
Mrazek DA, Biernacka JM, McAlpine DE et al (2014) Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol 34:313–317. https://doi.org/10.1097/JCP.0000000000000099
Mueller EM, Burgdorf C, Chavanon ML et al (2014) The COMT Val158Met polymorphism regulates the effect of a dopamine antagonist on the feedback-related negativity. Psychophysiology 51:805–809. https://doi.org/10.1111/PSYP.12226
Murphy LE, Fonseka TM, Bousman CA, Müller DJ (2021) Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry. https://doi.org/10.1038/s41380-021-01340-6
Musil R, Zill P, Seemüller F et al (2013) Genetics of emergent suicidality during antidepressive treatment – data from a naturalistic study on a large sample of inpatients with a major depressive episode. Eur Neuropsychopharmacol 23:663–674. https://doi.org/10.1016/J.EURONEURO.2012.08.009
Myung W, Kim J, Lim S-W et al (2015) A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry 5:e633–e633. https://doi.org/10.1038/tp.2015.127
Nagy H, Goda K, Fenyvesi F et al (2004) Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun 315:942–949. https://doi.org/10.1016/j.bbrc.2004.01.156
Narasimhan S, Aquino TD, Multani PK et al (2012) Variation in the catechol-O-methyltransferase (COMT) gene and treatment response to venlafaxine XR in generalized anxiety disorder. Psychiatry Res 198:112–115. https://doi.org/10.1016/J.PSYCHRES.2011.12.034
Nemeroff CB, Owens MJ (2003) Neuropharmacology of paroxetine. Psychopharmacol Bull 37(Suppl 1)
Ni YG, Miledi R (1997) Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci U S A 94:2036–2040. https://doi.org/10.1073/PNAS.94.5.2036
Nichols AI, Focht K, Jiang Q et al (2011) Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 31:155–167. https://doi.org/10.2165/11586630-000000000-00000
Nielsen KK, Flinois JP, Beaune P, Brøsen K (1996) The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277
Niitsu T, Fabbri C, Bentini F, Serretti A (2013) Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 45:183–194. https://doi.org/10.1016/J.PNPBP.2013.05.011
Nikisch G, Eap CB, Baumann P (2008) Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacol Res 58:344–347. https://doi.org/10.1016/J.PHRS.2008.09.010
Nishizawa D, Iseki M, Arita H et al (2021) Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia. Mol Pain 17. https://doi.org/10.1177/1744806921999924
Nojimoto FD, Mueller A, Hebeler-Barbosa F et al (2010) The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat α1B-adrenoceptors. Neuropharmacology 59:49–57. https://doi.org/10.1016/J.NEUROPHARM.2010.03.015
Noordam R, Sitlani CM, Avery CL et al (2017) A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. J Med Genet 54:313–323. https://doi.org/10.1136/JMEDGENET-2016-104112
O’Brien FE, Clarke G, Fitzgerald P et al (2012) Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol 166:1333–1343. https://doi.org/10.1111/J.1476-5381.2012.01858.X
O’Connell CP, Goldstein-Piekarski AN, Nemeroff CB et al (2018) Antidepressant outcomes predicted by genetic variation in corticotropin-releasing hormone binding protein. Am J Psychiatry 175:251–261. https://doi.org/10.1176/APPI.AJP.2017.17020172
Obach RS, Cox LM, Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262–270. https://doi.org/10.1124/DMD.104.002428
Olesen OV, Linnet K (1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 25
Onali P, Dedoni S, Olianas MC (2010) Direct agonist activity of tricyclic antidepressants at distinct opioid receptor subtypes. J Pharmacol Exp Ther 332:255–265. https://doi.org/10.1124/JPET.109.159939
Oslin DW, Lynch KG, Shih MC et al (2022) Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial. JAMA 328:151–161. https://doi.org/10.1001/JAMA.2022.9805
Otton SV, Ball SE, Cheung SW et al (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149–156. https://doi.org/10.1111/J.1365-2125.1996.TB00173.X
Özdemir V, Naranjo CA, Shulman RW et al (1998) Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 18:198–207. https://doi.org/10.1097/00004714-199806000-00004
Özdoǧan ÜK, Lähdesmäki J, Mansikka H, Scheinin M (2004) Loss of amitriptyline analgesia in α2A-adrenoceptor deficient mice. Eur J Pharmacol 485:193–196. https://doi.org/10.1016/j.ejphar.2003.11.047
Ozomaro U, Wahlestedt C, Nemeroff CB (2013) Personalized medicine in psychiatry: problems and promises. BMC Med 11:132. https://doi.org/10.1186/1741-7015-11-132
Pae CU (2011) Desvenlafaxine in the treatment of major depressive disorder. Expert Opin Pharmacother 12:2923–2928. https://doi.org/10.1517/14656566.2011.636033
Pain O, Hodgson K, Trubetskoy V et al (2022) Identifying the common genetic basis of antidepressant response. Biol Psychiatry Glob Open Sci 2:115–126. https://doi.org/10.1016/J.BPSGOS.2021.07.008
Pälvimäki EP, Roth BL, Majasuo H et al (1996) Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor. Psychopharmacology (Berl) 126:234–240. https://doi.org/10.1007/BF02246453
Pastoor D, Gobburu J (2014) Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol 10:121–128. https://doi.org/10.1517/17425255.2014.863873
Peddi S, Roth BL, Glennon RA, Westkaemper RB (2004) Structural determinants for high 5-HT2A receptor affinity of spiro[9,10-dihydroanthracene]-9,3′-pyrrolidine (SpAMDA). Bioorg Med Chem Lett 14:2279–2283. https://doi.org/10.1016/j.bmcl.2004.02.014
Peng L, Gu L, Li B, Hertz L (2014) Fluoxetine and all other SSRIs are 5-HT2B agonists – importance for their therapeutic effects. Curr Neuropharmacol 12:365–379. https://doi.org/10.2174/1570159X12666140828221720
Pérez V, Salavert A, Espadaler J et al (2017) Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry 17:250. https://doi.org/10.1186/s12888-017-1412-1
Perlis RH, Adams DH, Fijal B et al (2010) Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. J Clin Psychiatry 71:599–605. https://doi.org/10.4088/JCP.08m04632gre
Perlis RH, Dowd D, Fava M et al (2020) Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety 37:834–841. https://doi.org/10.1002/DA.23029
Peroutka SJ, Snyder SH (1982) Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1:658–659. https://doi.org/10.1016/S0140-6736(82)92206-1
Perroud N, Aitchison KJ, Uher R et al (2009) Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 34:2517–2528. https://doi.org/10.1038/NPP.2009.81
Perroud N, Uher R, Ng MYM et al (2012) Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. Pharmacogenomics J 12:68–77. https://doi.org/10.1038/TPJ.2010.70
Perry R, Cassagnol M (2009) Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. Clin Ther 31(Pt 1):1374–1404. https://doi.org/10.1016/J.CLINTHERA.2009.07.012
Porcelli S, Fabbri C, Serretti A (2012) Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 22:239–258. https://doi.org/10.1016/J.EURONEURO.2011.10.003
Preskorn S, Patroneva A, Silman H et al (2009) Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 29:39–43. https://doi.org/10.1097/JCP.0B013E318192E4C1
Punke MA, Friederich P (2007) Amitriptyline is a potent blocker of human Kv1.1 and Kv7.2/7.3 channels. Anesth Analg 104:1256–1264. https://doi.org/10.1213/01.ANE.0000260310.63117.A2
Rafeyan R, Papakostas GI, Jackson WC, Trivedi MH (2020) Inadequate response to treatment in major depressive disorder. J Clin Psychiatry 81:27570. https://doi.org/10.4088/JCP.OT19037BR3
Rajamani S, Eckhardt LL, Valdivia CR et al (2006) Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol 149:481–489. https://doi.org/10.1038/SJ.BJP.0706892
Ramey K, Ma JD, Best BM et al (2014) Variability in metabolism of imipramine and desipramine using urinary excretion data. J Anal Toxicol 38:368–374. https://doi.org/10.1093/JAT/BKU034
Rao N (2007) The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 46:281–290. https://doi.org/10.2165/00003088-200746040-00002
Rasmussen B, Maenpaa J, Pelkonen O et al (1995) Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br J Clin Pharmacol 39:151–159. https://doi.org/10.1111/J.1365-2125.1995.TB04422.X
Rasmussen BB, Nielsen TL, Brøsen K (1998) Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 83:240–245. https://doi.org/10.1111/J.1600-0773.1998.TB01476.X
Relling MV, Klein TE (2011) CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther 89:464–467. https://doi.org/10.1038/clpt.2010.279
Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448. https://doi.org/10.1081/DMR-120001392
Roberts RL, Joyce PR, Mulder RT et al (2002) A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2:191–196. https://doi.org/10.1038/SJ.TPJ.6500099
Roth BL (1994) Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry 6:67–78. https://doi.org/10.3109/10401239409148985
Rudberg I, Hermann M, Refsum H, Molden E (2008) Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. Eur J Clin Pharmacol 64:1181–1188. https://doi.org/10.1007/S00228-008-0533-3
Ruike Z, Junhua C, Wenxing P (2010) In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol 25:553–559. https://doi.org/10.1002/HUP.1152
Rush AJ, Fava M, Wisniewski SR et al (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142. https://doi.org/10.1016/S0197-2456(03)00112-0
Ryu S, Park S, Lee JH et al (2017) A study on CYP2C19 and CYP2D6 polymorphic effects on pharmacokinetics and pharmacodynamics of amitriptyline in healthy Koreans. Clin Transl Sci 10:93–101. https://doi.org/10.1111/CTS.12451
Saiz-Rodríguez M, Belmonte C, Román M et al (2018) Effect of polymorphisms on the pharmacokinetics, pharmacodynamics and safety of sertraline in healthy volunteers. Basic Clin Pharmacol Toxicol 122:501–511. https://doi.org/10.1111/BCPT.12938
Sánchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467–489. https://doi.org/10.1023/A:1006986824213
Sanchez C, Reines EH, Montgomery SA (2014) A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 29:185–196. https://doi.org/10.1097/YIC.0000000000000023
Sangkuhl K, Klein TE, Altman RB (2011) PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics 21:769–772. https://doi.org/10.1097/FPC.0B013E328346063F
Sangkuhl K, Stingl JC, Turpeinen M et al (2014) PharmGKB summary: venlafaxine pathway. Pharmacogenet Genomics 24:62–72. https://doi.org/10.1097/FPC.0000000000000003
Sapena R, Morin D, Zini R et al (1996) Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes. Eur J Pharmacol 300:159–162. https://doi.org/10.1016/0014-2999(96)00060-X
Sargent PA, Quested DJ, Cowen PJ (1998) Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors. Psychopharmacology (Berl) 140:120–122. https://doi.org/10.1007/S002130050747
Sasayama D, Hiraishi A, Tatsumi M et al (2013) Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. Pharmacogenomics J 13:354–358. https://doi.org/10.1038/tpj.2012.18
Sawamura K, Suzuki Y, Someya T (2004) Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 60:553–557. https://doi.org/10.1007/S00228-004-0792-6
Sawynok J, Esser MJ, Reid AR (1999) Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain 82:149–158. https://doi.org/10.1016/S0304-3959(99)00043-3
Schatzberg AF, DeBattista C, Lazzeroni LC et al (2015) ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry 172:751–759. https://doi.org/10.1176/APPI.AJP.2015.14050680
Schiele MA, Zwanzger P, Schwarte K et al (2021) Serotonin transporter gene promoter hypomethylation as a predictor of antidepressant treatment response in major depression: a replication study. Int J Neuropsychopharmacol 24:191–199. https://doi.org/10.1093/IJNP/PYAA081
Sebben M, Ansanay H, Bockaert J, Dumuis A (1994) 5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. Neuroreport 5:2553–2557. https://doi.org/10.1097/00001756-199412000-00037
Shahlaei M, Rahimi B, Nowroozi A et al (2015) Exploring binding properties of sertraline with human serum albumin: combination of spectroscopic and molecular modeling studies. Chem Biol Interact 242:235–246. https://doi.org/10.1016/J.CBI.2015.10.006
Shams MEE, Arneth B, Hiemke C et al (2006) CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 31:493–502. https://doi.org/10.1111/j.1365-2710.2006.00763.x
Shan X, Zhao W, Qiu Y et al (2019) Preliminary clinical investigation of combinatorial pharmacogenomic testing for the optimized treatment of depression: a randomized single-blind study. Front Neurosci 13. https://doi.org/10.3389/FNINS.2019.00960
Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M (2020) Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements. Clin Pharmacol Ther 107:1240–1255. https://doi.org/10.1002/cpt.1720
Shin JG, Park JY, Kim MJ et al (2002) Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 30:1102–1107. https://doi.org/10.1124/DMD.30.10.1102
Shrestha SS, Pine DS, Luckenbaugh DA et al (2014) Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model. Neurosci Lett 559:163–168. https://doi.org/10.1016/J.NEULET.2013.11.034
Singh H, Becker PM (2007) Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs 16:1295–1305. https://doi.org/10.1517/13543784.16.8.1295
Solomon HV, Cates KW, Li KJ (2019) Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res 271:604–613. https://doi.org/10.1016/J.PSYCHRES.2018.12.053
Stahl SM (2008) Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr 13:1027–1038. https://doi.org/10.1017/S1092852900017089
Stahl SM, Hauger RL, Rausch JL et al (1993) Downregulation of serotonin receptor subtypes by nortriptyline and adinazolam in major depressive disorder: neuroendocrine and platelet markers. Clin Neuropharmacol 16(Suppl 3):S19–S31
Steimer W, Zöpf K, Von Amelunxen S et al (2004) Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 50:1623–1633. https://doi.org/10.1373/CLINCHEM.2003.030825
Stingl JC, Brockmöller J, Viviani R (2013) Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 18:273–287. https://doi.org/10.1038/MP.2012.42
Suhara T, Takano A, Sudo Y et al (2003) High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60:386–391. https://doi.org/10.1001/ARCHPSYC.60.4.386
Suzuki Y, Sugai T, Fukui N et al (2011) CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 25:908–914. https://doi.org/10.1177/0269881110370504
Swen JJ, van der Wouden CH, Manson LE et al (2023) A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 401(10374):347–356. https://doi.org/10.1016/S0140-6736(22)01841-4
Szewczuk-Bogusławska M, Kiejna A, Beszłej JA et al (2004) Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol 56
Takano H, Arakawa R, Nogami T et al (2014) Norepinephrine transporter occupancy by nortriptyline in patients with depression: a positron emission tomography study with (S,S)-[18F]FMeNER-D2. Int J Neuropsychopharmacol 17:553–560. https://doi.org/10.1017/S1461145713001521
Tang SW, Helmeste D (2008) Paroxetine. Expert Opin Pharmacother 9:787–794. https://doi.org/10.1517/14656566.9.5.787
Tansey KE, Guipponi M, Perroud N et al (2012) Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. PLoS Med 9:e1001326. https://doi.org/10.1371/journal.pmed.1001326
Tassaneeyakul W, Birkett DJ, Miners JO (1998) Inhibition of human hepatic cytochrome P4502E1 by azole antifungals, CNS-active drugs and non-steroidal anti-inflammatory agents. Xenobiotica 28:293–301. https://doi.org/10.1080/004982598239579
Tatsumi M, Groshan K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258. https://doi.org/10.1016/S0014-2999(97)01393-9
Tatsumi M, Jansen K, Blakely RD, Richelson E (1999) Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol 368:277–283. https://doi.org/10.1016/S0014-2999(99)00005-9
Taylor MJ, Sen S, Bhagwagar Z (2010) Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 68:536–543. https://doi.org/10.1016/J.BIOPSYCH.2010.04.034
Teschemacher AG, Seward EP, Hancox JC, Witchel HJ (1999) Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128:479–485. https://doi.org/10.1038/SJ.BJP.0702800
Thase ME, Parikh SV, Rothschild AJ et al (2019) Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial. J Clin Psychiatry 80. https://doi.org/10.4088/JCP.19M12910
Thiele LS, Ishtiak-Ahmed K, Thirstrup JP et al (2022) Clinical impact of functional CYP2C19 and CYP2D6 gene variants on treatment with antidepressants in young people with depression: a danish cohort study. Pharmaceuticals (Basel) 15. https://doi.org/10.3390/PH15070870
Thomas DR, Nelson DR, Johnson AM (1987) Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 93:193–200. https://doi.org/10.1007/BF00179933
Thomas L, Mulligan J, Mason V et al (2008) GENetic and clinical predictors of treatment response in depression: the GenPod randomised trial protocol. Trials 9. https://doi.org/10.1186/1745-6215-9-29
Tiwari AK, Zai CC, Altar CA et al (2022) Clinical utility of combinatorial pharmacogenomic testing in depression: a Canadian patient- and rater-blinded, randomized, controlled trial. Transl Psychiatry 12. https://doi.org/10.1038/S41398-022-01847-8
Toll L, Berzetei-Gurske IP, Polgar WE et al (1998) Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr 178
Tsai MH, Lin KM, Hsiao MC et al (2010) Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 11:537–546. https://doi.org/10.2217/PGS.09.168
Tsuchimine S, Ochi S, Tajiri M et al (2018) Effects of cytochrome P450 (CYP) 2C19 genotypes on steady-state plasma concentrations of escitalopram and its desmethyl metabolite in Japanese patients with depression. Ther Drug Monit 40:356–361. https://doi.org/10.1097/FTD.0000000000000506
Uher R, Perroud N, Ng MYM et al (2010) Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 167:555–564. https://doi.org/10.1176/appi.ajp.2009.09070932
Urakami Y, Okuda M, Masuda S et al (2001) Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res 18:1528–1534. https://doi.org/10.1023/A:1013070128668
Vaishnavi SN, Nemeroff CB, Plott SJ et al (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55:320–322. https://doi.org/10.1016/j.biopsych.2003.07.006
van der Lee M, Allard WG, Vossen RHAM et al (2021) Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Sci Transl Med 13. https://doi.org/10.1126/scitranslmed.abf3637
van Schaik RHN, Müller DJ, Serretti A, Ingelman-Sundberg M (2020) Pharmacogenetics in psychiatry: an update on clinical usability. Front Pharmacol 11:575540. https://doi.org/10.3389/fphar.2020.575540
van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M, Jukić MM (2020) Pharmacogenomics of antidepressant and antipsychotic treatment: how far have we got and where are we going? Front Psych 11:94. https://doi.org/10.3389/fpsyt.2020.00094
Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (1999) Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 39:567–577. https://doi.org/10.1177/00912709922008173
Venkatakrishnan K, Von Moltke LL, Greenblatt DJ (2001) Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther 297
Virtanen R, Iisalo E, Irjala K (1982) Protein binding of doxepin and desmethyldoxepin. Acta Pharmacol Toxicol (Copenh) 51:159–164. https://doi.org/10.1111/J.1600-0773.1982.TB01008.X
Visscher PM, Wray NR, Zhang Q et al (2017) 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet 101:5–22. https://doi.org/10.1016/J.AJHG.2017.06.005
Waade RB, Hermann M, Moe HL, Molden E (2014) Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol 70:933–940. https://doi.org/10.1007/S00228-014-1696-8
Watanabe J, Suzuki Y, Fukui N et al (2008) Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration. Ther Drug Monit 30:705–708. https://doi.org/10.1097/FTD.0B013E31818D73B3
Weinshenker D, White SS, Javors MA et al (2002) Regulation of norepinephrine transporter abundance by catecholamines and desipramine in vivo. Brain Res 946:239–246. https://doi.org/10.1016/S0006-8993(02)02889-5
Weiss J, Dormann SMG, Martin-Facklam M et al (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197–204. https://doi.org/10.1124/JPET.102.046532
Wen B, Ma L, Zhu M (2008) Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact 173:59–67. https://doi.org/10.1016/J.CBI.2008.02.001
Werling LL, Keller A, Frank JG, Nuwayhid SJ (2007) A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp Neurol 207:248–257. https://doi.org/10.1016/J.EXPNEUROL.2007.06.013
Whirl-Carrillo M, McDonagh EM, Hebert JM et al (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414–417. https://doi.org/10.1038/clpt.2012.96
Wigmore EM, Hafferty JD, Hall LS et al (2020) Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. Pharmacogenomics J 20:329–341. https://doi.org/10.1038/S41397-019-0067-3
Wiles NJ, Mulligan J, Peters TJ et al (2012) Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry 200:130–136. https://doi.org/10.1192/BJP.BP.110.091223
Wiles NJ, Fischer K, Cowen P et al (2014) Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial. Psychol Med 44:2855–2866. https://doi.org/10.1017/S0033291714000221
Winner JG, Carhart JM (2013) A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med 16
Wolking S, Schaeffeler E, Lerche H et al (2015) Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 54:709–735. https://doi.org/10.1007/S40262-015-0267-1
Wu X, Kekuda R, Huang W et al (1998) Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem 273:32776–32786. https://doi.org/10.1074/JBC.273.49.32776
Wu X, Huang W, Prasad PD et al (1999) Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 290
Wu X, Wei H, Ganapathy ME et al (2000) Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol 279. https://doi.org/10.1152/AJPRENAL.2000.279.3.F449
Yalcin I, Choucair-Jaafar N, Benbouzid M et al (2009) beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol 65:218–225. https://doi.org/10.1002/ANA.21542
Yoon YR, Cha IJ, Shon JH et al (2000) Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 67:567–576. https://doi.org/10.1067/MCP.2000.106128
Yuan Z, Chen Z, Xue M et al (2020) Application of antidepressants in depression: a systematic review and meta-analysis. J Clin Neurosci 80:169–181. https://doi.org/10.1016/j.jocn.2020.08.013
Zanardi R, Serretti A, Rossini D et al (2001) Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50:323–330. https://doi.org/10.1016/S0006-3223(01)01118-0
Żebrowska-Łupina I (1980) Presynaptic α-adrenoceptors and the action of tricyclic antidepressant drugs in behavioural despair in rats. Psychopharmacology (Berl) 71:169–172. https://doi.org/10.1007/BF00434407
Zhong H, Haddjeri N, Sánchez C (2012) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter – a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 219:1–13. https://doi.org/10.1007/S00213-011-2463-5
Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 48:689–723. https://doi.org/10.2165/11318030-000000000-00000
Zhou S-F, Zhou Z-W, Yang L-P, Cai J-P (2009) Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16:3480–3675. https://doi.org/10.2174/092986709789057635
Zhou D, Guo J, Linnenbach AJ et al (2010) Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos 38:863–870. https://doi.org/10.1124/DMD.109.030981
Zhou Y, Zhang G, Rao Z et al (2015) Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. Arch Pharm Res 38:1325–1335. https://doi.org/10.1007/S12272-014-0539-6
Zhou Y, Ingelman-Sundberg M, Lauschke VM (2017) Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 102:688–700. https://doi.org/10.1002/CPT.690
Zou YF, Ye DQ, Feng XL et al (2010) Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder. Eur Neuropsychopharmacol 20:535–544. https://doi.org/10.1016/J.EURONEURO.2009.12.005
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tsermpini, E.E., Serretti, A., Dolžan, V. (2023). Precision Medicine in Antidepressants Treatment. In: Cascorbi, I., Schwab, M. (eds) Precision Medicine. Handbook of Experimental Pharmacology, vol 280. Springer, Cham. https://doi.org/10.1007/164_2023_654
Download citation
DOI: https://doi.org/10.1007/164_2023_654
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-40046-9
Online ISBN: 978-3-031-40047-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)